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REVIEW

Role of non-immune mechanisms of muscle
damage in idiopathic inflammatory myopathies
William Coley, Sree Rayavarapu and Kanneboyina Nagaraju*

Abstract
Idiopathic inflammatory myopathies (IIMs) comprise a
group of autoimmune diseases that are characterized
by symmetrical skeletal muscle weakness and
muscle inflammation with no known cause. Like
other autoimmune diseases, IIMs are treated with
either glucocorticoids or immunosuppressive drugs.
However, many patients with an IIM are frequently
resistant to immunosuppressive treatments, and
there is compelling evidence to indicate that not
only adaptive immune but also several non-immune
mechanisms play a role in the pathogenesis of these
disorders. Here, we focus on some of the evidence
related to pathologic mechanisms, such as the
innate immune response, endoplasmic reticulum
stress, non-immune consequences of MHC class I
overexpression, metabolic disturbances, and hypoxia.
These mechanisms may explain how IIM-related
pathologic processes can continue even in the face
of immunosuppressive therapies. These data indicate
that therapeutic strategies in IIMs should be directed
at both immune and non-immune mechanisms of
muscle damage.

Introduction
The term ‘idiopathic inﬂammatory myopathy’ (IIM)
usually refers to one of three related diseases: polymyositis (PM), dermatomyositis (DM), and inclusion body
myositis (IBM). Each variation of the disease has deﬁning
characteristics (for example, the heliotrope rash of DM or
the intramuscular rimmed vacuoles of IBM), but there
are some common characteristics. In PM and DM,
patients typically present clinically with diﬀuse muscle
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weakness that is worse in proximal muscles than in distal
muscles, whereas in IBM profound weakness may be
present in both proximal and distal muscles. Histologically, patients show muscle inﬂammation, ﬁber degeneration, and overexpression of the MHC class I molecule
[1-3]. This muscle pathology is not always uniform, and
many patients display isolated patches of inﬂammation
and degeneration in otherwise healthy muscle tissue. In
aﬀected patients, signiﬁcant causes of morbidity and
mortality include diﬃculty in performing daily activities,
dysphagia, and respiratory failure [4,5]. Immunosuppressive therapies such as prednisolone and methotrexate are
common ﬁrst-line treatments, with cyclosporine and
other powerful immunosuppressants as second-line agents
[6-8]. Unfortunately, these current therapies have produced mixed results; for example, patients with DM are
most likely to beneﬁt from glucocorticoid therapy (with a
reduction in inﬂammation, and improvement in muscle
function), and most PM patients typically respond to
immunosuppressive therapy [9-11]. On the other hand,
patients with IBM (and a subset of PM patients) do not
typically respond to either glucocorticoids or other
immunosuppressant therapies [7]. Studies have shown
that the therapeutic response to glucocorticoid treatment
varies signiﬁcantly; furthermore, the degrees of inﬂammatory inﬁltration and muscle function are dissociated,
suggesting a role for other mechanisms in muscle dysfunction in these diseases [12,13]. Here we review some
of the non-adaptive immune mechanisms that may be
responsible for muscle weakness in the absence of overt
inﬂammation, and we provide evidence that skeletal
muscle, but not inﬂammation, is an active participant in
the progression of muscle disease in these disorders.

Toll-like receptors on skeletal muscle
It is generally thought that skeletal muscle is merely a
target of immune-mediated damage and that removal of
immune cells from the milieu could result in preservation
of skeletal muscle and improvement in skeletal muscle
function. However, the fact that disease progression occurs
in the absence of signiﬁcant inﬂammation suggests that
skeletal muscle itself contributes to the disease process.
How the skeletal muscle senses signals from the injured
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microenvironment clearly requires further study. Mammalian cells are able to rapidly and eﬃciently recognize
not only foreign invaders such as microbes but also
damage- or injury-associated self-proteins via germlineencoded pattern recognition receptors. These receptors
recognize damage-associated molecular patterns (DAMPs),
which are either derived from pathogens (pathogenassociated molecular patterns, or PAMPs) or are selfproteins (stress or danger-associated molecular patterns,
or SAMPs) [14,15]. Recognition of damage-associated
molecular patterns by Toll-like receptors (TLRs) initiates
a signaling cascade, leading to the activation or inhibition
of genes that control the inﬂammatory response.
In chronic inﬂammatory conditions such as myositis,
some of the self-proteins released from damaged cells
may act as SAMPs. TLRs are known to sense several of
these endogenous ligands and activate inﬂammatory
signaling pathways [16]. It is important to consider this
mechanism of inﬂammation since some IIM patients can
continue to experience muscle ﬁber degeneration even
after successful suppression of autoreactive lymphocytes.
In IIMs, several endogenous inﬂammatory molecules
(such as high mobility group box 1 (HMGB1), which is
discussed in more detail later) have been proposed to
play a role in disease pathogenesis [17,18]. Two separate
investigations of patient biopsies have identiﬁed TLR-3
and TLR-7 (receptors for double-stranded RNA and GUrich single-stranded RNA, respectively) on the surface of
regenerating muscle ﬁbers in patient biopsies [19,20].
TLRs have also been observed on skeletal muscle cells in
other myopathies, where the activation of the innate
immune pathway caused the skeletal muscle cells to
secrete the inﬂammatory cytokine IL-1β [21]. Interestingly, the U1-snRNP molecule, which is capable of
activating both TLR-3 and TLR-7, has been previously
reported to be associated with several autoimmune
rheumatoid diseases, and a small number of IIM patients
develop anti-U1 autoantibodies [22,23]. Both HMGB1
and U1-snRNP are nuclear proteins that are not found in
the extracellular space in healthy tissue, thereby suggesting that these endogenous TLR ligands may be released
from inﬂamed or necrotic ﬁbers, which then induce
inﬂammation in neighboring ﬁbers.

Skeletal muscle cells secrete several cytokines and
chemokines
Cytokines play a central role in the immune response by
promoting the activation of antigen-speciﬁc and nonspeciﬁc eﬀector mechanisms and tissue repair. Most
discussions about cytokines revolve around their production from lymphocytes, but it is important to consider
cytokines that are produced from the skeletal muscle
itself. Human skeletal muscle cells constitutively produce
the cytokine IL-6, and its expression can be increased by
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stimulation with IL-1α, IL-1β, TNFα and IFNγ in a dosedependent manner [24,25]. IL-6 has a role in regulating
metabolic rates in skeletal muscle, but it can also act as
an inﬂammatory molecule. Excessive secretion of IL-6
has previously been linked to other autoimmune diseases
(for example, rheumatoid arthritis) and is known to
promote the development of potentially autoreactive
TH-17 cells [26,27]. The pathogenic role of IL-6 in
myositis has also been supported by IL-6 blockade in one
mouse model of C-protein-induced myositis [28]. In IL-6
knockout mice, both the incidence and the severity of
myositis were reduced compared to C57BL/6 controls. It
should also be noted that previous examinations of
muscle biopsies from IIM patients have found ﬁbers that
were positive for IL-1α, TNFα, and IL-1β staining,
suggesting that lymphocytes may not be necessary to
induce overexpression of IL-6 [29,30]. Furthermore, it
has been suggested that a feedback loop linking IL-6
production and TLR-3 stimulation exists in inﬂamed
skeletal muscle, and may play a role in the pathogenesis
of IIMs [19].
Apart from IL-6, recent investigations have conﬁrmed
that IFNα plays a prominent role in the pathogenesis of
IIMs [31-35]. Inquiries into the sources of some of the
type I IFNs have indicated that dendritic cells and mast
cells are the major producers of IFNα and IFNβ in DM
patients. These same cells are also known to be major
producers of IL-1β [36,37]. IFNα is known to upregulate
a number of antiviral target genes, such as MXA, IFIT2,
and ISG15. Strong intramuscular staining for these IFNα
targets has previously been observed in biopsies from
DM and PM patients [34]. One such target, ISG15, is
known to disrupt the normal ubiquitination process.
During viral infections, ISG15 is substituted for ubiquitin
and interferes with the maturation and function of viral
proteins, such as the HIV Gag and Ebola VP40 proteins.
Histological examination of muscle biopsies has revealed
that ISG15 is absent from healthy muscle but is detectable in patients with PM, IBM, and DM [35]. Further
experiments are still needed to establish the functional
consequences of ISG15 expression in muscle cells. The
clinical signiﬁcance of IFNα was underscored in a small
study in which IIM patients failed to respond to
inﬂiximab, and a worsening in symptoms was correlated
with an increase in IFNα serum levels [31].
In addition to classical cytokines, non-traditional
cytokines/chemokines also appear to play a signiﬁcant
role in controlling the inﬂammatory process. Two such
proteins, histidyl tRNA synthetase (HisRS) and HMGB1,
have been associated with myositis [18,38,39]. The
inﬂammatory properties of the HMGB1 protein have
previously been demonstrated in other inﬂammatory
diseases [40-42]. This non-histone nuclear protein acts as
a potent inﬂammatory molecule when released from

Coley et al. Arthritis Research & Therapy 2012, 14:209
http://arthritis-research.com/content/14/2/209

necrotic cells. HMGB1-mediated inﬂammation is signaled
through either TLR-4 or receptor for advanced glycation
endproducts (RAGE) [43]. Examination of human muscle
biopsies has revealed that cytoplasmic HMGB1 expression is widespread in PM and DM patients but absent
from healthy controls. Furthermore, when isolated primary
muscles ﬁbers are exposed to extracellular HMGB1 in
vitro, the ﬁbers begin expressing MHC class I antigens on
their surface and demonstrate an accelerated, dosedependent eﬄux of calcium ions [17], suggesting a role
for HMGB1 in the perpetuation of inﬂammation and
muscle ﬁber degeneration even in the absence of
inﬁltrating lymphocytes.

Role of MHC class I upregulation on skeletal muscle
fibers
MHC class I proteins are essential for immune surveillance. They are expressed on nearly all cells, with few
exceptions (for example, mature neurons, oligodendrocytes, pancreatic islet cells, and skeletal muscle ﬁbers). In
these few cases, constitutive expression is either low or
absent. As mentioned previously, one of the histological
hallmarks of skeletal muscle in IIM is the widespread and
constitutive presence of MHC class I protein [44-47].
Even though the immunological roles of these proteins
(for example, antigen presentation) are well-studied, their
non-immunological roles are not well deﬁned. It is
worthwhile to mention that other autoimmune diseases
(for example, type I diabetes or multiple sclerosis) can be
initiated by forced expression of the MHC class I in the
few cell types (that is, pancreatic islet or oligodendrocyte
cells) where it is normally absent [48,49]. It is not clear
why MHC class I expression is restricted in these cell
types, but one possible explanation can be found in
recent research into the formation and maintenance of
the neuromuscular junction (NMJ). Recent studies of
neurons in the central nervous system have indicated
that MHC class I expression is dynamic (as is that of its
secondary receptors, CD3z and PirB) and is involved in
communication across the synaptic junction and the
maintenance of synaptic plasticity [50,51]. These studies
have indicated that classical MHC class I proteins are
expressed in motor neurons, with predominant expression occurring at the presynaptic end of the NMJ. In
another recent study, it was reported that a knockout of
the MHC class I gene resulted in abnormally high
densities of NMJs during development, and abnormal
formation of NMJs after denervation and re-innervation
[52]. Together, these reports suggest that MHC class I
acts as a signaling molecule to promote pruning NMJs
during development and potentially to force the
remodeling of established NMJs. This newly discovered
role for MHC class I may explain why its expression is so
tightly controlled by the cells surrounding the NMJ
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(neurons, oligodendrocytes, and muscle ﬁbers). Under
this model, the constitutive expression of MHC class I
from the muscle may have a disruptive eﬀect on the
structure and/or function of the NMJ, though this
hypothesis has not yet been tested.

The endoplasmic reticulum stress response pathway
Endoplasmic reticulum (ER) stress is a known cause of
pathology in certain conditions, including viral infections
and neurodegenerative disorders, and there is emerging
evidence that ER stress within the muscle cells
contributes to pathology in IIMs [53]. The ER is known as
the site of protein synthesis, folding, post-translational
modiﬁcation, lipid biosynthesis, and intracellular calcium
storage within the cell. Since muscle contractions are
signaled through calcium release, the regulation of intracellular calcium concentrations is of paramount importance in muscle cells. Within muscle cells, the ER is a
specially modiﬁed organelle that is also known as the
sarcoplasmic reticulum. Excessive changes in the load of
proteins, composition of lipids, or calcium concentration
within the ER can trigger multiple stress response pathways acting through ATF4 (activating transcription
factor 4), ATF6 (activating transcription factor 6), and
PERK (protein kinase RNA-like endoplasmic reticulum
kinase). If the ER stress cannot be resolved, then the cell
will initiate an apoptotic response via the expression of
DDIT3 (DNA-damage-inducible transcript; also called
CHOP) and activation of caspase 4 (or caspase-11 and
caspase-12 in mice) [54-56]. Interestingly, there is some
evidence to suggest that mature skeletal muscle, like
pancreatic islet cells, may tax the sarcoplasmic reticulum
to near its limits, even under conditions of normal
protein synthesis [57].
We and others have suggested that, in myositis, overexpression of the MHC class I molecule in skeletal
muscle can induce ER stress. This hypothesis is based
upon observations made in the transgenic mouse model
of myositis [45,46,58] and in human patients with IIMs
[47,59,60]. As described previously, skeletal muscle cells
do not express detectable levels of MHC class I molecules
under normal conditions, although transient expression
can be observed following injury or viral infections. In
the mouse model of myositis, the forced expression of
MHC class I molecules is suﬃcient to precipitate the
onset of myositis in mice. Histological and biochemical
examinations of the mouse muscle tissue revealed ER
stress in muscle ﬁbers, as evidenced by the upregulation
of multiple ER chaperone proteins (for example, Grp78,
Grp94, calnexin, calreticulin) and activation of the NF-κB
pathway. Very similar changes were found in patients in
whom muscle cells that were positive for MHC class I
were also found to show increased expression of Grp78,
Grp94, and calreticulin [47,61-63]. It should also be

Coley et al. Arthritis Research & Therapy 2012, 14:209
http://arthritis-research.com/content/14/2/209

noted that lymphocytic inﬁltration was not correlated
with staining for ER stress markers [47].
Several laboratories have examined the potential role of
ER stress and ER stress-associated degradation in the
accumulation of misfolded proteins in IBM patients.
Histological analysis of patients with IBM has shown
scattered inclusion bodies (thought to be protein
aggregates) that are not seen in PM or DM. The appearance of inclusion bodies can be hypothesized to be
indicative of defective protein folding or defective degradation of misfolded proteins, although the available
evidence seems to favor defective degradation. Examination of patients with IBM has revealed that the mRNA
and protein expression of amyloid-B protein and BACE1
(β-site amyloid-β precursor protein (AβPP)-cleaving
enzyme 1) are increased in IBM muscle. However, it
should be noted that the potential pathogenic role of βamyloid in IBM is a controversial topic [64,65]. In a
separate investigation, patients with IBM were found to
exhibit an increased expression of autophagosomes, a
common ER stress response. Furthermore, the proteases
cathepsin B and cathepsin D in patients with IBM
showed diminished protease activity when compared to
those in controls. These data indicate that increased ER
stress and protein aggregation may be the result of
impaired protein degradation in IIMs [66].

Metabolic disturbances
Another potential mechanistic explanation for the
persistent muscle weakness seen in IIMs comes from the
observation that there is an apparent disturbance in
patients’ metabolism and ATP production. Muscle ﬁbers
are generally composed of type I (slow-twitch) and
type II (fast-twitch) ﬁbers. Muscles composed of slow
ﬁbers depend on oxidative phosphorylation and are
responsible for long-term, low-force muscle activity.
Conversely, muscles composed of fast-twitch ﬁbers often
depend on glycolysis in order to carry out rapid,
strenuous movements. However, in the case of IIM
patients, there are indications that the fast-twitch ﬁbers
are more prone to degenerate, and that these patients’
ability to produce ATP in the skeletal muscle may be
impaired. Mass spectrometry analysis of myositis
biopsies has shown a signiﬁcant loss of type II (fasttwitch)-speciﬁc proteins (for example, myosin heavy
chain 1 (MYH1), troponin T3 (TNNT3), and actinin 3
(ACTN3)) and a modest increase in type I (slow-twitch)
muscle proteins (for example, myosin heavy chain 7
(MYH7), troponin T1 (TNNTL1), and actinin 2 (ACNT2))
[64]. Similarly, IIM patients have shown a modest
decrease in enzymes required for glycolysis in the muscle
(for example, glycogen debranching enzyme (AGL),
muscle phosphofructokinase (PFKM), fructose-1,6-bisphosphatase isozyme 2 (FBP2), and phosphoglycerate
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mutase 2 (PGAM)), with the most signiﬁcant decreases
being found in patients with IBM [64].
In recent decades, the results of multiple studies have
indicated that the loss of another type II-speciﬁc muscle
enzyme, AMPD1, is potentially responsible for disturbances in ATP metabolism and muscle weakness [67,68].
These ﬁndings have been corroborated by magnetic
resonance spectroscopy in patients with juvenile-onset
DM; in that study, the stable isotope 31P was used to
compare the levels of ATP, ADP, AMP, and phosphocreatine in the quadriceps of DM patients and healthy
controls. The DM patients were found to have roughly
4.03 ± 0.26 mmoles/kg of total ATP, compared to
6.26 ± 0.23 mmoles/kg in the controls. The concentrations of ADP, AMP, and phosphocreatine were similarly
decreased in the DM patients [69]. Interestingly, there is
some evidence that chronic ER stress can alter the
metabolism of muscle ﬁbers: activation of the unfolded
protein response pathway in skeletal muscle has been
reported to occur during exercise, with repeated
activation of this pathway being linked to a gradual shift
in muscle metabolism to adapt to exercise training. In
addition, the transcriptional coactivator PGC-1α (peroxisome proliferator-activated receptor gamma coactivator
1-alpha) has been found to interact with ATF6; prior
investigations have linked PGC-1α to a role in promoting
type I muscle ﬁber genes, and ATF6 has been shown to
be activated by ER stress. It is interesting to note that
mice deﬁcient in ATF6 have an impaired ability to
recover from exercise, while mice lacking PGC-1α experience exercise intolerance that can be partially reversed
by inhibitors of CHOP [70]. Taken together, these results
suggest that ER stress has important consequences for
metabolic homeostasis and force generation in skeletal
muscle cells.

Role of hypoxia
Histological analysis of muscle from some IIM patients
has shown that these patients have fewer capillaries per
unit area in their skeletal muscle than do healthy patients
[71,72]. This observation has led investigators to propose
that the resulting lower oxygen levels are responsible for
the muscle weakness seen in myositis patients. Gene
proﬁling of patient biopsies has revealed that both promoters of angiogenesis (for example, hypoxia inducible
factor (HIF)-1α, CD146, and ﬁbronectin) and inhibitors
of angiogenesis (for example, CXCL10, transforming
growth factor-β, and angiopoietin 2) are expressed simultaneously, indicating that capillaries are being actively
remodeled in patients with myositis [73]. The transcription factor HIF-1α is especially noteworthy because it is a
direct sensor of hypoxia and helps to maintain oxygen
homeostasis. A recent publication has corroborated these
expression proﬁling data by demonstrating that HIF-1
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convergence on the production of inﬂammatory cytokines. These data also explain why immune suppression
is variable in terms of its eﬃcacy in restoring muscle
strength, because the innate dysfunction of myoﬁbers
remains despite the achievement of successful immune
suppression.
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Figure 1. Relationship between the possible pathologic
mechanisms leading to idiopathic inflammatory myopathies.
ER, endoplasmic reticulum; MHC, major histocompatibility complex;
TLR, Toll-like receptor.

proteins accumulate in IIM patients [71,74]. This accumulation is possible only under low-oxygen conditions,
indicating that the skeletal muscle of all IIM patients are
very likely subjected to hypoxic conditions. This hypoxia
hypothesis is supported by the reported beneﬁts of
physical exercise in myositis patients, suggesting a role
for vascular endothelial cell dysfunction and hypoxia in
the pathogenesis of IIMs [72,75].

Conclusion
The evidence to support a role for non-immune mechanisms in the pathogenesis of IIMs is growing. These data
place the myoﬁber at the center of disease pathobiology,
with an initial insult to the myoﬁbers (whether viral,
damage, or a genetic predisposition) leading to myoﬁber
TLR signaling, which in and of itself can induce weakness
via type 1 IFN pathways by interfering with energy
production and mitochondrial respiration. Inﬁltrating
leukocytes augment and exacerbate this signaling. The
relationship between all of these pathologic mechanisms
is shown in Figure 1, with a special emphasis on their
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